Larry Norton

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Is cancer a disease of self-seeding?
    Larry Norton
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Med 12:875-8. 2006
  2. ncbi request reprint Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:3943-51. 2013
  3. doi request reprint Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 131:111-6. 2012
  4. doi request reprint Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 17:3490-9. 2011
  5. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
  6. doi request reprint Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:4125-31. 2011
  7. pmc Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Sarat Chandarlapaty
    Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6784-91. 2012
  8. doi request reprint Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:5461-8. 2011
  9. doi request reprint Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Solid Tumor Oncology, New York, NY 10065, USA
    Clin Breast Cancer 13:239-246.e1. 2013
  10. pmc A CXCL1 paracrine network links cancer chemoresistance and metastasis
    Swarnali Acharyya
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 150:165-78. 2012

Detail Information

Publications93

  1. ncbi request reprint Is cancer a disease of self-seeding?
    Larry Norton
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Nat Med 12:875-8. 2006
  2. ncbi request reprint Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer
    Patrick G Morris
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer 119:3943-51. 2013
    ..The incidence of congestive heart failure (CHF) at a median follow-up of 2 years was 1.4% and 3.2%, respectively...
  3. doi request reprint Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA
    Breast Cancer Res Treat 131:111-6. 2012
    ..Capecitabine 7-7 with lapatinib was well tolerated with minimal gastrointestinal toxicity. Antitumor activity was observed in patients with trastuzumab-refractory MBC...
  4. doi request reprint Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib
    Patrick G Morris
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 17:3490-9. 2011
    ....
  5. doi request reprint A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) ā†’ nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  6. doi request reprint Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer
    Devika Gajria
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:4125-31. 2011
    ..Bevacizumab has demonstrated the ability to improve outcomes when it is added to chemotherapy, including capecitabine, in the first-line and second-line settings...
  7. pmc Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer
    Sarat Chandarlapaty
    Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 18:6784-91. 2012
    ..We conducted a prospective tissue acquisition study to determine if there is evidence for these lesions in metastatic tumors that have progressed on trastuzumab-containing therapy...
  8. doi request reprint Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:5461-8. 2011
    ..Therefore, a retrospective, single-institution, sequential cohort study of women with small, node-negative, HER2+ breast cancer who did or did not receive adjuvant trastuzumab was conducted...
  9. doi request reprint Randomized phase II trial of weekly vs. every 2 weeks vs. every 3 weeks nanoparticle albumin-bound paclitaxel with bevacizumab as first-line chemotherapy for metastatic breast cancer
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, Department of Medicine, Division of Solid Tumor Oncology, New York, NY 10065, USA
    Clin Breast Cancer 13:239-246.e1. 2013
    ..This trial was designed to further develop nab-P by evaluating its efficacy and safety using every 3 weeks (q3w), every 2 weeks (q2w), or weekly scheduling in combination with bevacizumab as first-line treatment of MBC...
  10. pmc A CXCL1 paracrine network links cancer chemoresistance and metastasis
    Swarnali Acharyya
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cell 150:165-78. 2012
    ..This network of endothelial-carcinoma-myeloid signaling interactions provides a mechanism linking chemoresistance and metastasis, with opportunities for intervention...
  11. doi request reprint DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors
    Yong H Wen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 36:1700-8. 2012
    ....
  12. pmc Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer
    Ayca Gucalp
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Breast Cancer 11:306-11. 2011
    ..We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)(-) and progesterone receptor (PR)(-) metastatic breast cancer (MBC)...
  13. ncbi request reprint Living with metastatic breast cancer: a qualitative analysis of physical, psychological, and social sequelae
    Catherine E Mosher
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Breast J 19:285-92. 2013
    ....
  14. doi request reprint Id4 protein is highly expressed in triple-negative breast carcinomas: possible implications for BRCA1 downregulation
    Yong Hannah Wen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Breast Cancer Res Treat 135:93-102. 2012
    ..Our results document substantial expression of Id4 in most TNBCs, which could result in functional downregulation of BRCA1 pathways in these tumors...
  15. doi request reprint Clinical implications of cancer self-seeding
    Elizabeth Comen
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill College of Medicine of Cornell University, New York, NY 10021, USA
    Nat Rev Clin Oncol 8:369-77. 2011
    ..Indeed, reframing our understanding of metastasis within the self-seeding model offers new opportunities for prevention and cure of metastatic cancer...
  16. pmc Spreaders and sponges define metastasis in lung cancer: a Markov chain Monte Carlo mathematical model
    Paul K Newton
    Department of Aerospace and Mechanical Engineering, Viterbi School of Engineering, University of Southern California, Los Angles 90089, USA
    Cancer Res 73:2760-9. 2013
    ..The model shows that the combined characteristics of the primary and the first metastatic site to which it spreads largely determine the future pathways and timescales of systemic disease...
  17. doi request reprint Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer
    Elizabeth Comen
    Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill College of Medicine of Cornell University, New York, NY 10021, USA
    J Mammary Gland Biol Neoplasia 17:241-9. 2012
    ....
  18. pmc Breast cancer methylomes establish an epigenomic foundation for metastasis
    Fang Fang
    Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Sci Transl Med 3:75ra25. 2011
    ..These findings significantly enhance our understanding of breast cancer oncogenesis and aid the development of new prognostic biomarkers for this common malignancy...
  19. pmc TGF-Ī²-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition
    Marko Stankic
    Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, 415 East 68 th Street, New York, NY 10065, USA Department of Molecular Biology, Weill Cornell Medical College, 445 East 69 th Street, New York, NY 10021, USA
    Cell Rep 5:1228-42. 2013
    ..Collectively, these studies underscore the importance of Id-mediated phenotypic switching during distinct stages of breast cancer metastasis. ..
  20. doi request reprint Self-seeding in cancer
    Elizabeth Comen
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Recent Results Cancer Res 195:13-23. 2012
    ..Indeed, redirecting our research and treatment efforts within the self-seeding model may offer new possibilities for eradicating metastatic cancer...
  21. doi request reprint HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Clin Cancer Res 17:5132-9. 2011
    ..On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-positive breast cancer...
  22. pmc Randomised trial of expressive writing for distressed metastatic breast cancer patients
    Catherine E Mosher
    Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Avenue, 7th Floor, New York, NY 10022, USA
    Psychol Health 27:88-100. 2012
    ..26%, respectively; pā€‰<ā€‰0.05). Findings suggest that expressive writing may improve the uptake of mental health services among distressed cancer patients, but is not broadly effective as a psychotherapeutic intervention...
  23. pmc Tumor entrained neutrophils inhibit seeding in the premetastatic lung
    Zvi Granot
    Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    Cancer Cell 20:300-14. 2011
    ..Thus, whereas tumor-secreted factors contribute to tumor progression at the primary site, they concomitantly induce a neutrophil-mediated inhibitory process at the metastatic site...
  24. pmc The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis
    Qing Chang
    Department of Medicine, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
    Neoplasia 15:848-62. 2013
    ....
  25. pmc Optimizing chemotherapy dose and schedule by Norton-Simon mathematical modeling
    Tiffany A Traina
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Breast Dis 31:7-18. 2010
    ..to hasten and improve anticancer drug development, we created a novel approach to generating and analyzing preclinical dose-scheduling data so as to optimize benefit-to-toxicity ratios...
  26. pmc Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 28:2982-8. 2010
    ..We conducted a pilot study of dose-dense AC followed by PT plus lapatinib (PTL) followed by trastuzumab plus lapatinib (TL)...
  27. doi request reprint Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy
    Rebecca Waitz
    Department of Immunology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 72:430-9. 2012
    ..Although cryoablation is currently used to treat a targeted tumor nodule, our results suggest that combination therapy with CTLA-4 blockade will augment antitumor immunity and rejection of tumor metastases in this setting...
  28. pmc Association between bone mineral density and incidence of breast cancer
    Merav Fraenkel
    Endocrine Unit, Columbia University Medical Center, New York, New York, United States of America
    PLoS ONE 8:e70980. 2013
    ..The primary objective of this study was to assess whether BMD is associated with risk of subsequent breast cancer occurrence in the female population of southern Israel...
  29. pmc MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer
    Kim J Png
    Laboratory of Systems Cancer Biology, Rockefeller University, New York, NY 10065, USA
    Genes Dev 25:226-31. 2011
    ..We furthermore identify miR-335 as a robust inhibitor of tumor reinitiation. We thus implicate the miR-335 locus on 7q32.2 as the first selective metastasis suppressor and tumor initiation suppressor locus in human breast cancer...
  30. pmc Tumor self-seeding by circulating cancer cells
    Mi Young Kim
    Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cell 139:1315-26. 2009
    ..Tumor self-seeding could explain the relationships between anaplasia, tumor size, vascularity and prognosis, and local recurrence seeded by disseminated cells following ostensibly complete tumor excision...
  31. ncbi request reprint Dose-dense chemotherapy for breast cancer: what does the future hold?
    Patrick G Morris
    Evelyn H Lauder Breast Center, 300 E 66th St, New York, NY 10065, USA
    Future Oncol 6:951-65. 2010
    ..Newer targeted agents may be similarly incorporated into dose-dense regimens to further improve patient outcomes. This article reviews dose-dense therapy and discusses its role as a chemotherapy foundation for additional targeted agents...
  32. doi request reprint Intracystic papillary carcinoma of the breast: An in situ or invasive tumor? Results of immunohistochemical analysis and clinical follow-up
    Christine A Wynveen
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 35:1-14. 2011
    ..This type of tumor is strongly estrogen receptor positive and hormonal therapy should be pursued for its management, whereas the benefit of radiation after lumpectomy remains unclear...
  33. ncbi request reprint American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  34. pmc SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers
    Sarat Chandarlapaty
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:240-8. 2008
    ..However, the utility of these drugs has been limited by their hepatotoxicity, poor solubility, and poorly tolerated formulations...
  35. pmc Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by
    Minetta C Liu
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, DC 20007 2198, USA
    Cancer Treat Rev 34:223-30. 2008
    ..A secondary aim was to assess if a higher dose (10 mcg/kg/day) of G-CSF is more efficacious than the conventional dose (5 mcg/kg/day) in this setting...
  36. pmc Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping
    Adam B Olshen
    Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BMC Genet 9:14. 2008
    ..435,632 SNPs overlapped and met annotation criteria in the two groups...
  37. pmc Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study
    Noah D Kauff
    Clinical Genetics and Gynecology Services, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 192, New York, NY 10021, USA
    J Clin Oncol 26:1331-7. 2008
    ....
  38. ncbi request reprint Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:5410-7. 2007
    ..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...
  39. doi request reprint Changing indications for surgery in patients with stage IV breast cancer: a current perspective
    Mary Morrogh
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 112:1445-54. 2008
    ..To determine whether such developments have influenced clinical practice, the authors evaluated surgical practice patterns in the study institution over the last 15 years...
  40. doi request reprint The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer
    Chau Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 713, New York, NY 10021, USA
    J Clin Oncol 26:1216-22. 2008
    ..The primary end point was cardiac safety, and the secondary end points were time to recurrence and overall survival...
  41. doi request reprint Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up
    Lee K Tan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1803-9. 2008
    ..However, there is no consensus regarding the optimal method for pathologic examination of SLN, or the prognostic significance of SLN micrometastases...
  42. doi request reprint Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen
    Paul E Goss
    Massachusetts General Hospital Cancer Center, 55 Fruit St, Lawrence House, LRH 302, Boston, MA 02114, USA
    J Clin Oncol 26:1948-55. 2008
    ..When the trial was unblinded, patients who received placebo (PLAC) were offered LET...
  43. doi request reprint Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leu
    Andrew D Seidman
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 26:1642-9. 2008
    ..Because inhibition of HER-family signaling had potential efficacy even without HER-2 overexpression, we randomly assigned for trastuzumab in this population...
  44. doi request reprint Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
    Michael P Digiovanna
    Yale University School of Medicine, Section of Medical Oncology, 333 Cedar St, Room WWW 217, New Haven, CT 06510, USA
    J Clin Oncol 26:2364-72. 2008
    ....
  45. doi request reprint Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:1797-802. 2008
    ....
  46. ncbi request reprint Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041)
    Gretchen Kimmick
    Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157, USA
    Invest New Drugs 22:83-9. 2004
    ..Good performance status was the most important predictor of survival. In this group of women with metastatic breast cancer, the overall prognosis was poor. This combination of rIL-2 and IFN was ineffective...
  47. ncbi request reprint HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both...
  48. ncbi request reprint Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience
    Hyman B Muss
    University of Vermont, Vermont Cancer Center, Burlington, VT 05405, USA
    J Clin Oncol 25:3699-704. 2007
    ..We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy...
  49. ncbi request reprint Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukemia Group B correlative science study from protocols 8541/8869
    Anthony J Guidi
    North Shore Medical Center, Salem, MA, USA
    J Clin Oncol 20:732-42. 2002
    ..However, the utility of this assay in node-positive patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil (CAF) has not been well studied...
  50. ncbi request reprint Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments
    Chau T Dang
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4062-7. 2004
    ....
  51. ncbi request reprint Cytokeratin-positive cells in sentinel lymph nodes in breast cancer are not random events: experience in patients undergoing prophylactic mastectomy
    Tari A King
    Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 101:926-33. 2004
    ..In the current study, we address this question by examining the pattern of SLN involvement in patients undergoing prophylactic mastectomy (PM) at Memorial Sloan-Kettering Cancer Center (New York, NY)...
  52. ncbi request reprint Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer
    Kevin S Hughes
    Avon Comprehensive Breast Evaluation Center, Breast Ovarian Cancer Genetics and Risk Assessment Program, Massachusetts General Hospital, Division of Surgical Oncology, Boston 02114, USA
    N Engl J Med 351:971-7. 2004
    ..In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy...
  53. ncbi request reprint The Gompertzian view: Norton honored for role in establishing cancer treatment approach
    Charles Schmidt
    J Natl Cancer Inst 96:1492-3. 2004
  54. ncbi request reprint A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 101:2509-15. 2004
    ....
  55. ncbi request reprint Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: cancer and leukemia group B 9344
    Carolyn I Sartor
    Dept of Radiation Oncology, University of North Carolina School of Medicine, CB7512, Chapel Hill, NC 27599, USA
    J Clin Oncol 23:30-40. 2005
    ....
  56. ncbi request reprint Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series
    Mark Robson
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 103:44-51. 2005
    ..The current study evaluates the appropriateness of breast-conserving therapy (BCT) in women with BRCA mutations...
  57. ncbi request reprint Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer
    Hyman B Muss
    Fletcher Allen Health Care, Vermont Cancer Center, Burlington, VT 05401, USA
    JAMA 293:1073-81. 2005
    ....
  58. ncbi request reprint Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA
    William P Peters
    Cancer and Leukemia Group B, 230 W Monroe St, Suite 2050, Chicago, IL 60606, USA
    J Clin Oncol 23:2191-200. 2005
    ..The prognosis for women with primary breast cancer involving multiple axillary nodes remains poor. High-dose chemotherapy with stem-cell support produced promising results in initial clinical trials conducted at single institutions...
  59. ncbi request reprint Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342
    Eric P Winer
    Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 22:2061-8. 2004
    ..Cancer and Leukemia Group B Protocol 9342 was initiated to determine the optimal dose of paclitaxel administered as a 3-hour infusion every 3 weeks to women with metastatic breast cancer...
  60. pmc A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
    Mark E Robson
    Research Institute of McGill University Health Centre, Cancer Prevention Centre, McGill University, Montreal, Quebec, Canada
    Breast Cancer Res 6:R8-R17. 2004
    ..The prognostic significance of germline mutations in BRCA1 and BRCA2 in women with breast cancer remains unclear. A combined analysis was performed to address this uncertainty...
  61. ncbi request reprint Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers
    Lauren Scheuer
    Clinical Genetics, Breast Cancer Medicine, and Developmental Chemotherapy Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:1260-8. 2002
    ..To prospectively determine the impact of genetic counseling and testing on risk-reduction strategies and cancer incidence in a cohort of individuals at hereditary risk for breast and ovarian cancer...
  62. ncbi request reprint Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer
    Catherine Van Poznak
    Breast Cancer Medicine Service, The Pathology Department, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2319-26. 2002
    ..g., HER2, EGFR), and estrogen receptors and progesterone receptors. These molecular markers and their correlation with clinical taxane sensitivity are investigated in this retrospective clinicopathologic study...
  63. ncbi request reprint Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation
    Noah D Kauff
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1609-15. 2002
    ..We prospectively compared the effect of risk-reducing salpingo-oophorectomy with that of surveillance for ovarian cancer on the incidence of subsequent breast cancer and BRCA-related gynecologic cancers in women with BRCA mutations...
  64. ncbi request reprint Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancer
    Shanu Modi
    Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:3665-73. 2002
    ..To prospectively evaluate the association between tumor response, change in quality of life (QoL), and hospital expenditures in patients with metastatic breast cancer (MBC) receiving single-agent paclitaxel...
  65. ncbi request reprint Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer
    I Craig Henderson
    University of California at San Francisco, San, Francisco, CA 94143, USA
    J Clin Oncol 21:976-83. 2003
    ..This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival...
  66. ncbi request reprint Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia
    Marc L Citron
    ProHEALTH Care Associates, LLP, 2800 Marcus Ave, Lake Success, NY 11042, USA
    J Clin Oncol 21:1431-9. 2003
    ....
  67. ncbi request reprint Factors influencing treatment patterns of breast cancer patients age 75 and older
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Crit Rev Oncol Hematol 46:121-6. 2003
    ..To retrospectively determine the factors influencing treatment decisions in older breast cancer patients at a single center...
  68. ncbi request reprint Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B
    Raymond B Weiss
    Walter Reed Army Medical Center, Washington, DC, USA
    J Clin Oncol 21:1825-35. 2003
    ....
  69. ncbi request reprint Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia
    Kenneth Offit
    Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 95:1548-51. 2003
    ..Individuals who carry a germline BRCA2 mutation and who plan to have children with a partner of Ashkenazi Jewish descent should consider undergoing genetic counseling...
  70. ncbi request reprint A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast Cancer Res Treat 90:157-63. 2005
    ..Breast cancer has variable expression of KIT and PDGFR therefore we conducted a phase II trial to evaluate the safety and efficacy of imatinib in patients with metastatic breast cancer (MBC)...
  71. ncbi request reprint A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 6:55-60. 2005
    ..Gemcitabine was delivered at a dose of 800 mg/m2 on days 1, 8, and 15 of a 28-day cycle until evidence of disease progression...
  72. ncbi request reprint Breast cancer: a tale of two centuries: with implications for understanding cancer metastasis and cancer stem cell biology
    Bruce A Chabner
    AlphaMed Press, 318 Blackwell Street, Suite 260, Durham, North Carolina 27701 2884, USA
    Oncologist 10:369. 2005
  73. ncbi request reprint Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Breast Cancer Res Treat 98:343-8. 2006
    ..This longitudinal prospective study describes the older breast cancer patient's perception of the cognitive impact of adjuvant chemotherapy...
  74. ncbi request reprint Use of dose-dense chemotherapy in the management of breast cancer
    Larry Norton
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Adv Hematol Oncol 4:36-7. 2006
  75. pmc Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer
    Donald A Berry
    University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    JAMA 295:1658-67. 2006
    ..Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy...
  76. ncbi request reprint A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
    Shanu Modi
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Breast Cancer 7:270-7. 2006
    ..Preclinical studies have indicated a synergistic effect for the combination of anti-EGFR therapy plus paclitaxel in breast cancer models...
  77. ncbi request reprint Pharmacokinetics and toxicity of weekly docetaxel in older patients
    Arti Hurria
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Clin Cancer Res 12:6100-5. 2006
    ....
  78. ncbi request reprint Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer
    Tiffany A Traina
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Oncologist 11:1070-1. 2006
  79. ncbi request reprint Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:223-7. 2007
    ..We conducted a pilot trial to assess the feasibility of dose-dense chemotherapy consisting of a standard regime at 10- to 11-day intervals in the adjuvant/neoadjuvant setting. A 2-day window was allowed for scheduling logistics...
  80. ncbi request reprint Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17
    Paul E Goss
    Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 25:2006-11. 2007
    ..MA.17 randomized postmenopausal women after 5 years of tamoxifen, to letrozole or placebo. We present outcomes according to tumor receptor status...
  81. ncbi request reprint Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21
    Teresa A Gilewski
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:2977-85. 2007
    ..To determine the clinical toxicities and antibody response against sTn and tumor cells expressing sTn following immunization of high-risk breast cancer patients with clustered sTn-KLH [sTn(c)-KLH] conjugate plus QS-21...
  82. ncbi request reprint Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:295-300. 2006
    ..Analyses were conducted to examine the relationships between duration of treatment on MA.17 and outcomes...
  83. ncbi request reprint Localization of breast cancer susceptibility loci by genome-wide SNP linkage disequilibrium mapping
    Nathan A Ellis
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genet Epidemiol 30:48-61. 2006
    ..While these results demonstrate the feasibility of genome-wide association strategies, further application of this approach will critically depend on optimizing the density and distribution of SNPs and the size and type of study design...
  84. ncbi request reprint Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy
    Larry Norton
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021 6007, USA
    Oncologist 10:370-81. 2005
    ..These new insights may lead us to change the thrust of our attack from genes involved in mitosis to those involved in metastasis, including metastasis to self, and to use and further improve dose-dense regimens...
  85. ncbi request reprint Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, NY 10021, New York, USA
    Breast Cancer Res Treat 92:151-6. 2005
    ..To retrospectively determine the relationship of age to toxicity from adjuvant chemotherapy for breast cancer...
  86. ncbi request reprint Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients
    Lynn G Dressler
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7295, Mason Farm Rd, Chapel Hill, NC 27599 7295, USA
    J Clin Oncol 23:4287-97. 2005
    ....
  87. ncbi request reprint Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
    Monica N Fornier
    Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 104:1575-9. 2005
    ....
  88. ncbi request reprint Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17
    Paul E Goss
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Natl Cancer Inst 97:1262-71. 2005
    ..This report presents updated findings from the trial...
  89. ncbi request reprint Effect of creatinine clearance on patterns of toxicity in older patients receiving adjuvant chemotherapy for breast cancer
    Arti Hurria
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Drugs Aging 22:785-91. 2005
    ..We sought to determine the association between calculated creatinine clearance (CL(CR)) and grade 3 or 4 toxicities during adjuvant chemotherapy in women > or =65 years of age with breast cancer...
  90. ncbi request reprint Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk?
    Kathryn Beal
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Breast J 11:317-20. 2005
    ..Sequencing of RT after taxane therapy with a target interval of 3-4 weeks does not appear to result in increased pulmonary toxicity and is associated with good local control...
  91. ncbi request reprint Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families
    Noah D Kauff
    Department of Gynecology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 97:1382-4. 2005
    ..66 was expected (SIR = 1.52, 95% CI = 0.02 to 8.46; P = .48). These results suggest that women from BRCA mutation-negative, site-specific breast cancer families are not at increased risk for ovarian cancer...
  92. ncbi request reprint Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer
    Shanu Modi
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Invest 23:483-7. 2005
    ..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments...
  93. ncbi request reprint Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis
    Tari A King
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Ann Surg Oncol 14:2510-8. 2007
    ..However, several lines of evidence suggest that phenotypic effects may result from BRCA haploinsufficiency...